Introduction
============

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, recurrent diseases that affect mainly young people.[@b1-jir-12-127]--[@b3-jir-12-127] Although these diseases have undetermined etiology, research advances have outlined some of the pathways by which they occur: 1) genetic predisposition associated with the environment induces a disruption of the intestinal microbial flora, 2) the epithelial cells and the immune system of the intestine itself determine the risk of developing the disease.[@b4-jir-12-127]--[@b6-jir-12-127]

Risk factors are related to damage to the intestinal mucosa barrier that induces increased permeability, causing a greater antibody antigen reaction and generating an exacerbated inflammatory response.[@b7-jir-12-127] Additionally, the increase in thrombotic phenomena in CD patients using oral contraceptives supports the hypothesis of participation in these vascular events.[@b8-jir-12-127],[@b9-jir-12-127] Surgical procedures such as appendectomy could induce an imbalance of the immune system, generating an inflammatory response that is exacerbated in patients with CD.[@b10-jir-12-127] Another contributing factor is related to the residence of susceptible people, whereby residents of urban areas would be at greater risk due to pollution and excessive hygiene. Interestingly, local factors even seem to contribute to the development of IBD, which has been observed mainly in studies with immigrants who transition from low-incidence countries to high-incidence ones before adolescence, corroborating an increase in the number of people affected from high-incidence countries.[@b11-jir-12-127],[@b12-jir-12-127]

In certain regions in Brazil, IBD has been a major reason for missing work and school[@b13-jir-12-127]--[@b16-jir-12-127] and it affects mainly higher social classes. CD appears in people between 15 and 25 years of age, with the highest peak at 25 years of age, although other authors have stated that the highest incidence is between 30 and 40 years, while the disease is less frequent in people between the age of 60 and 70 years. Complementarily data have shown a higher prevalence among youngsters in recent years.[@b17-jir-12-127]--[@b25-jir-12-127] Unfortunately, in Brazil, epidemiological data are scarce and generally refer to the public health system, based on hospitalization records or records of patients who purchase high-cost medications through the government.[@b26-jir-12-127]--[@b31-jir-12-127] Although the main symptoms of the diseases are well-known in the literature, in Brazil up until now, there have been no studies on the main clinical signs and symptoms that could lead to investigation and diagnosis from the time of the onset of the symptoms to a defined diagnosis; in what way these diseases are present; which is the most frequent behavior; the associations of risk factors; what medical approaches have been attempted, and the incidence of complications over time.

Objectives
==========

1.  Establish the number of cases of IBD in an IBD private referral center in the Middle-West of Brazil.

2.  Analyze the location and behavior of the disease and medical management.

3.  Identify the association of extra-intestinal manifestations.

4.  Recognize the main clinical symptoms which led to the investigation and diagnosis of the inflammatory disease.

Methods
=======

This study was conducted during the period from 2003--2017 and was developed in a private referral center located in the Central West region of Brazil after approval of the ethics committee.

It was performed by way of analysis of electronic records with different variables formed by a standard questionnaire applied at the first consultation of the patients with inflammatory disease, considering risk factors, beginning with the first signs and symptoms and including the total time from onset of symptoms to diagnosis. The Montreal classification was used in both diseases, and drug approaches were recorded over time, along with the evolution and complications of the disease and any annual revisions (2004 to June 2017).

Diagnostic criteria: all patients underwent colonoscopy with biopsy. In cases of negative colonoscopy and suggestive symptomatology, the patients underwent double balloon enteroscopy or endoscopy. In cases of previous history of tuberculosis bacillus, testing was performed on tissue, and the tuberculin test was administered. In previous diagnostic situations, both the examinations and the slides were reviewed and updated, if necessary, for both diseases. In addition, inflammatory tests were performed, such as C-reactive protein and erythrocyte sedimentation rate, fecal culture for research and proto-parasitological analysis and serology for HIV.

Treatment criteria followed those indicated by the global literature, taking into account the location of the disease and its extent and behavior.[@b32-jir-12-127]--[@b34-jir-12-127]

Follow-up criteria: patients with active disease were followed weekly until the improvement of the clinical picture or stabilization of the serum levels of C-reactive protein, hemogram, and erythrocyte sedimentation rate (ESR). Following symptom stabilization, patients were seen every 6 months, and follow-up enrollment data were updated and revised each year.

All univariate and bivariate statistical analyses were performed on the sample. The proportions observed in the categories of these variables were tested using the chi-squared test (χ^2^), and differences were considered statistically significant when the risk of alpha error was lower than 0.05 (*P*\<0.05).

From the descriptive statistics, inferential tests were performed in tables, facilitating the interpretation of the association between the variables studied in the database. In addition, 95% CIs were calculated for the risk factors of the contingency tables. Statistical analyses were performed using the statistical software Minitab^®^ 16 (Minitab Inc, State College, PA, USA) and SAS (SAS Institute Inc., Cary, NC, USA).

Ethical approval
----------------

This study was approved by the Research Ethical Committee of the Universidade Estadual Paulista "Júlio de Mesquita Filho" (protocol number CAAE: 53006516.0.0000.5411). The Ethics Committee has granted exemption from obtaining informed consent of the participants as this is an analysis of a retrospective databank of de-identified data. In addition to this, the study involved patients who were over 18 years old. The patients who were under-aged were considered according to the age of diagnosis. At Clinica Scope only patients over 18 years old are accepted; the age factor was only used as an indication of when the disease started.

Results
=======

Three hundred and twenty-nine patients were diagnosed with IBD from July 2004 to December 2017; n=329: 212 had CD (64.4%) and 117 had UC (35.6%).

Age
---

The mean overall age was 38.12 years old (SD±14.91); 36.19 years old for CD patients (SD ±14.33) and 41.61 years old (SD±15.37) for UC patients (*P*=0.002).

Gender
------

There was a predominance of the female gender, corresponding to 72% of the overall study population (female:male ratio =*P*\<0.001) distributed between the diseases as follows: 50.5% in CD and 72.7% in UC (*P*\<0.001). The distribution of age according to the Montreal Classification was: A2 (55.6%) was higher than A3 (42%) and A1 (2.4%) ([Table 1](#t1-jir-12-127){ref-type="table"}).

Educational level
-----------------

Regarding the educational level, 4.0% had finished elementary school, 47.6% high school, and 48.5% graduated ([Table 1](#t1-jir-12-127){ref-type="table"}).

Disease phenotype of IBD patients
---------------------------------

According to the Montreal classification applied to both diseases, we noticed the following distributions regarding the behavior and side of the disease: CD and UC ([Table 2](#t2-jir-12-127){ref-type="table"}): there was no statistical significance.

Distribution of new cases over time
-----------------------------------

We noticed an increasing number of cases over time, with a peak in 2007 peak (*P*=0.046) ([Figure 1](#f1-jir-12-127){ref-type="fig"}).

Statistic analysis
------------------

Initially all variables were analyzed descriptively. For the quantitative variables, this analysis was done by observing the minimum and maximum values, and the calculation of means and SDs. Absolute and relative frequencies were calculated for the qualitative variables.

For the comparison of means of two groups, Student's *t*-test was used. To test homogeneity between proportions, the chi-squared test^(1)^ or the Fisher's exact test^(1)^ was used. The software used for the calculations was SPSS 17.0 for windows. The level of significance used for the tests was 5%.

Environmental factors
---------------------

In the analysis of environmental factors, 97% of the patients lived in an urban area, 15.5% of them smoked, 30.1% used anti-inflammatories, 10% used oral contraceptives, 17.9% had a family history of inflammatory disease, 9.7% had had appendectomies, and 6.7% had had tonsillectomies ([Table 3](#t3-jir-12-127){ref-type="table"}). Comparing the groups (CD and UC) in relation to the risk factors, no statistical difference was noticeable.

Main symptoms
-------------

Among the main symptoms that led to the investigation and diagnosis were diarrhea and bleeding (31.3%), weight loss (19.8%), diarrhea (18.5%), diarrhea and weight loss (12.2%), diarrhea and abdominal pain (11.3%), abdominal pain (6.4%), and bleeding (0.6%). The comparison between the groups is presented in [Table 4](#t4-jir-12-127){ref-type="table"}. Iñ70% of UC cases the first symptom was diarrhea/bleeding. In CD, 25% presented with weight loss and 25% with diarrhea. After analyzing the study groups in relation to the first symptoms, a statistical difference was noticed between the symptoms and the groups (*P*\<0.001) ([Table 4](#t4-jir-12-127){ref-type="table"}).

Time of diagnosis
-----------------

The time from symptom onset until definitive diagnosis was 62.4--76.3 months and was greater in UC patients ([Figure 2](#f2-jir-12-127){ref-type="fig"}).

Medication
----------

Among the drug approaches, the distribution during this time was 56.2% anti-TNFs, 44.4% mesalazine, 31.9% azathioprine, 13.7% Cipro and Flagyl, 8.5% probiotics, 3% methotrexate, 2.1% vedolizumab, 1.8% hyperbaric oxygen therapy, 0.6% cyclosporine, 0.3% tacrolimus, and 0.3% stem cells ([Table 5](#t5-jir-12-127){ref-type="table"}).

Extra-intestinal manifestations were present in 38.9% of cases, the most frequent being dry eye (17.6%), kidney stones (17.3%), and osteopenia (15.2%) ([Table 6](#t6-jir-12-127){ref-type="table"}).

Patients' follow-up
-------------------

Surgical approaches were much more frequent in CD patients. Of these patients, 15.9% had abscess drainage, 3.95% had endoscopic balloon dilation stenosis, 5.47% underwent resection of the small intestine, and 1.52% underwent surgical resection of stenotic lesions (0.91%). CD patients underwent a greater number of surgical approaches than those with UC (*P*\<0.001). During the study period, there were no cases of neoplasia, and one CD patient died due to complications inherent to the disease (intestinal obstruction).

Discussion
==========

Abundant evidence has revealed the increasing incidence of intestinal inflammatory diseases in the world. The different forms of presentations of the disease could be related to the influence of the environment in which it exists.[@b35-jir-12-127]--[@b39-jir-12-127] Therefore, it is considered of paramount importance to make an early diagnosis in order to quickly start treatment for these conditions.[@b40-jir-12-127]--[@b43-jir-12-127]

The research presented here followed 329 patients for 14 years; of these, 212 had CD, and 117 had UC ([Table 1](#t1-jir-12-127){ref-type="table"}). According to our data there was a greater number of cases of CD when compared to UC. It is likely that as CD is more severe than UC, patients suffering from this disease seek referral to IBD centers, although the literature has pointed out an increase in this disease all over the world.

National data show that in 2016, the per capita GDP of Brazil was USD8,649.95; the city of Campo Grande, the capital of Mato Grosso do Sul state, represented the third largest income, which is where this study was developed, in a private health care center that is a referral center for inflammatory intestinal diseases. Concerning the prevalence of female gender, patients of high cutural level, high sócio-economic status, high level of education, urban residency, and being employed in our data, and even though we have not found any statistical significance for these factors, this study reinforces similarities of epidemiological studies previ ously published in developed countries.[@b44-jir-12-127]--[@b46-jir-12-127] We also noticed that European descendants were the most affected by these diseases. This reflects the local population. Differently from Sousa et al's study, inflammatory diseases have been shown to be incapacitating where the patients were unable to study or work, with high rates of Brazilian government assistance.[@b16-jir-12-127] These conflicting results could reflect the difficulties these patients face in reaching a public referral center in this region.

For CD, the Montreal classification patterns showed the predominance of inflammatory behavior in B1 (68.9%), B2 (17%), B3 (7.6%) p 6.6%, and side in L3 (42.2%), L1 (37.4%), and L2 (19.9%) ([Table 2](#t2-jir-12-127){ref-type="table"}), with a side pattern compatible with that described in the literature. In the sample, inflammation was the most common, similar to that found by Parente et al.[@b28-jir-12-127],[@b47-jir-12-127],[@b48-jir-12-127] We can suggest that in our data, Chron's disease is more frequent. This is probably due to the fat that we are a referral center and our patients presented more severe diseases.

Regarding UC (Montreal classification), we noted that S1 and S2 were more frequent in this sample as well as E1 and E2 ([Table 2](#t2-jir-12-127){ref-type="table"}). This pattern was also similar to those found in the northeast and southeast, consistent with the global literature.[@b28-jir-12-127],[@b47-jir-12-127] Furthermore, we noticed an increasing number of new cases of the disease over time, with a peak in 2007 (*P*=0.046) ([Figure 1](#f1-jir-12-127){ref-type="fig"}).

Interestingly, Farrukh et al, during the period from 1996--2005, revealed that although the number of UC cases in Brazil increased over time, the rate of new-onset cases of CD increased steadily and was 18 times higher in 2005 than at the beginning of the study.[@b29-jir-12-127] Intriguingly, a Hispanic survey ended 1 year after the data collection at the private center in question began and could be a "mirror image" of what was happening in the country (namely, an increase in the incidence of CD, with a consequent reduction in UC).[@b29-jir-12-127]

Regarding the relationship between environmental factors and the diseases, current smoking, anti-inflammatories, oral contraceptives, prior tonsillectomy and appendectomy were evaluated during this time but they were not found to be statistically significant in this study.[@b49-jir-12-127]--[@b52-jir-12-127] This implies that there is a need for future studies that may connect the time of exposure to these factors in relation to the protection of the diseases or risk involved.

In this study, diarrhea was the predominant symptom, along with the presence of blood in the feces. When separately analyzing the diseases correlated with UC, bleeding and diarrhea were the most common (70%); however, in CD, there were a predominance of diarrhea (25.5%) and weight loss (25.5%), followed by others, as shown in [Table 4](#t4-jir-12-127){ref-type="table"}.

Our results were similar to the results of Delmondes et al, which described similar symptoms when analyzing patients with UC, finding a predominance of diarrhea with bleeding in 71% of the cases and only diarrhea for patients with CD (59%).[@b44-jir-12-127],[@b47-jir-12-127]

Our findings demonstrate that the time between clinical symptomatology and a definitive diagnostic investigation was 58--62 months (*P*\<0.77) ([Figure 2](#f2-jir-12-127){ref-type="fig"}). Previous studies referred to a period of 5--10 years for this interval.[@b53-jir-12-127],[@b54-jir-12-127] In our study, over time, Humira was used more frequently than Infliximab. This factor is probably due to the fact that we are a referral center treating patients whose previous treatments had failed, including infliximab.

Among the extra-intestinal manifestations, dry eye and kidney stones were the most frequent ([Table 6](#t6-jir-12-127){ref-type="table"}). Two previously published large, prospective studies with this same group of patients demonstrated the direct relationship between renal and dry eye and the use of mesalazine.[@b55-jir-12-127],[@b56-jir-12-127]

Despite the fact that some patients underwent surgery, we have not observed neoplasia up until now.

Conclusion
==========

This is an unpublished study developed in Brazil in a private health care center, since there have only been studies in this country in public centers and a large number of patients with inflammatory disease has been shown, with increasing numbers of these cases since 2007. Regarding clinical symptoms, diarrhea/bleeding followed by weight loss represented the major important signs that led to diagnosis, suggesting that more attention should be paid to an investigation which is quicker, aiming for an early diagnosis in order to avoid future complications of the inflammatory disease. The time to diagnosis was longer for patients with UC than for those with CD; the delay in diagnosis in Brazil is still a concern for these patients. Regarding drug approaches, biologic therapy represented \>50% of the drugs, showing that we had patients with severe disease in this series, in some cases reinforcing the indication for cellular transplantation, though in isolated situations. Therefore, IBD is not just a public health care reality, this study confirms the importance of being alert to the signs, and of recommending treatment sooner.
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###### 

Demographic characteristics of population (IBD patients) in a private health care center West of Brazil

  Variables                 n=329         CD (n=212)    UC (n=117)    *P*
  ------------------------- ------------- ------------- ------------- ---------
  Female gender             72 (72.0%)    107 (50.5%)   85 (72.7%)    \<0.001
  Age, years (mean±sD)      38.12±14.91   36.19±14.33   41.61±15.37   0.002
  Age (Montreal), n (%)                                               0.020
  A1                        8 (2.4%)      6 (2.8%)      2 (1.7%)      
  A2                        183 (55.6%)   129 (60.9%)   54 (46.2%)    
  A3                        138 (42.0%)   77 (36.3%)    61 (52.1%)    
  Education, n (%)                                                    0.340
  Elementary school         13 (4.0%)     9 (4.3%)      4 (3.4%)      
  High school               156 (47.6%)   94 (44.6%)    62 (53.0%)    
  Graduate                  159 (48.5%)   108 (51.1%)   51 (43.6%)    
  Ancestral origin, n (%)                                             0.221
  German                    21 (6.4%)     15 (7.1%)     6 (5.1%)      
  Italian                   81 (24.6%)    49 (23.1%)    32 (27.4%)    
  Japanese                  7 (2.1%)      7 (3.3%)      0 (0.0%)      
  Other                     82 (24.9%)    51 (24.1%)    31 (26.5%)    
  Portuguese                112 (34.0%)   70 (33.0%)    42 (35.9%)    
  Spanish                   26 (79%)      20 (9.4%)     6 (5.1%)      
  Urban resident            321 (97.6%)   207 (97.6%)   114 (97.4%)   1.000
  Employed, n (%)                                                     0.155
  No                        22 (6.7%)     15 (7.1%)     7 (6.0%)      
  Retired                   34 (10.4%)    16 (7.6%)     18 (15.4%)    
  Student                   5 (1.5%)      3 (1.4%)      2 (1.7%)      
  Yes                       267 (81.4%)   177 (83.9%)   90 (76.9%)    
  Religion, n (%)                                                     0.073
  Agnostic                  2 (0.6%)      1 (0.5%)      1 (0.9%)      
  Catholic                  238 (72.3%)   150 (70.8%)   88 (75.1%)    
  Spiritualist              1 (0.3%)      0 (0.0%)      1 (0.9%)      
  Spiritist (religion)      4 (1.2%)      4 (1.9%)      0 (0.0%)      
  Protestant/evangelical    32 (9.7%)     26 (12.3%)    6 (5.1%)      
  Not stated                52 (15.8%)    31 (14.6%)    21 (18.0%)    

**Abbreviations:** IBD, inflammatory bowel diseases; CD, Crohn's disease; UC, ulcerative colitis.

###### 

Clinical aspects of inflammatory bowel disease of UC patients

  Group                                          Age (Montreal classification)   *P*[\*](#tfn2-jir-12-127){ref-type="table-fn"}               
  ------- ------------------------- ------------ ------------------------------- ------------------------------------------------ ----------- -------
  CD      Behavior, n (%)                                                                                                                     0.116
          B1                        146 (68.9)   3 (50.0)                        82 (63.8)                                        61 (79.2)   
          B2                        36 (17.0)    2 (33.3)                        24 (18.6)                                        10 (13.0)   
          B3                        18 (7.6)     0 (0.0)                         12 (9.3)                                         4 (5.2)     
          P                         14 (6.6)     1 (1.7)                         11 (8.5)                                         2 (2.6)     
          Side, n (%)                                                                                                                         0.828
          L1                        79 (37.4)    3 (50.0)                        50 (39.1)                                        26 (33.8)   
          L2                        42 (19.9)    1 (16.7)                        25 (19.5)                                        16 (20.8)   
          L3                        89 (42.2)    2 (33.3)                        53 (41.4)                                        34 (44.2)   
          L4                        1 (0.5)      0 (0.0)                         0 (0.0)                                          1 (1.3)     
  UC      Disease severity, n (%)                                                                                                             0.591
          S0                        5 (4.4)      0 (0.0)                         3 (5.6)                                          2 (3.4)     
          S1                        47 (40.9)    0 (0.0)                         23 (42.6)                                        24 (40.7)   
          S2                        45 (39.1)    1 (50.0)                        22 (40.7)                                        22 (37.3)   
          S3                        18 (15.7)    1 (50.0)                        6 (11.1)                                         11 (18.6)   
          Disease extent, n (%)                                                                                                               0.707
          E1                        52 (45.2)    0 (0.0)                         26 (48.2)                                        26 (44.1)   
          E2                        49 (42.6)    2 (100.0)                       22 (40.7)                                        25 (42.4)   
          E3                        14 (12.2)    0 (0.0)                         6 (11.1)                                         8 (13.6)    

**Note:**

Descriptive level of probability of Fisher's exact test.

**Abbreviations:** UC, ulcerative colitis; CD, Crohn's disease.

###### 

Environmental risk factors for inflammatory bowel disease

  Variables                 Group       *P*                     
  ------------------------- ----------- ----------- ----------- -------
  Oral contraceptive pill   33 (10.0)   19 (9.0)    14 (1.0)    0.385
  Anti-inflammatory         99 (30.1)   65 (30.7)   34 (29.1)   0.762
  Smoking                   51 (15.5)   37 (175)    14 (12.0)   0.188
  Family influence          59 (17.9)   38 (17.9)   21 (18.0)   0.996
  Appendectomy              32 (9.7)    21 (9.9)    11 (9.4)    0.883
  Tonsillectomy             22 (6.7)    13 (6.1)    9 (7.7)     0.588

**Notes:** Data are presented as n (%).

**Abbreviations:** CD, Crohn's disease; UC, ulcerative colitis.

###### 

First symptoms in patients with inflammatory bowel diseases

  First symptoms            n=329        CD (n=212)   UC (n=117)
  ------------------------- ------------ ------------ ------------
  Diarrhea/bleeding         103 (31.3)   21 (9.9)     82 (70.1)
  Weight loss               65 (19.8)    54 (25.5)    11 (9.4)
  Diarrhea                  61 (18.5)    54 (25.5)    7 (6.0)
  Diarrhea/weight loss      40 (12.2)    34 (16.0)    6 (5.1)
  Diarrhea/abdominal pain   37 (11.3)    28 (13.2)    9 (7.7)
  Abdominal pain            21 (6.4)     21 (9.9)     0 (0.0)
  Bleeding                  2 (0.6)      0 (0.0)      2 (1.7)

**Notes:** Data are presented as n (%).

**Abbreviations:** CD, Crohn's disease; UC, ulcerative colitis.

###### 

Medication and medical approaches in inflammatory bowel disease patients

  Medication          (n=329)      CD (n=212)   UC (n=117)   
  ------------------- ------------ ------------ ------------ -------------------------------------------------
  Anti-TNF            185 (56.2)   133 (62.7)   52 (44.4)    0.001[a](#tfn8-jir-12-127){ref-type="table-fn"}
  5 AZA               146 (44.4)   95 (44.8)    51 (43.6)    0.831[a](#tfn8-jir-12-127){ref-type="table-fn"}
  Humira              145 (44.1)   104 (49.1)   41 (35.0)    0.014[a](#tfn8-jir-12-127){ref-type="table-fn"}
  AZA                 106 (31.9)   71 (33.5)    34 (29.1)    0.409[a](#tfn8-jir-12-127){ref-type="table-fn"}
  IFX                 96 (29.2)    73 (34.4)    23 (19.7)    0.005[a](#tfn8-jir-12-127){ref-type="table-fn"}
  Cipro               45 (13.7)    37 (17.5)    8 (6.8)      0.007[a](#tfn8-jir-12-127){ref-type="table-fn"}
  Flagyl              45 (13.7)    37 (17.5)    8 (6.8)      0.007[a](#tfn8-jir-12-127){ref-type="table-fn"}
  Probiotics          28 (8.5)     23 (10.9)    5 (4.3)      0.041[a](#tfn8-jir-12-127){ref-type="table-fn"}
  MTX                 10 (3.0)     10 (4.7)     0 (0.0)      0.016[b](#tfn9-jir-12-127){ref-type="table-fn"}
  Vedo                7 (2.1)      7 (3.3)      0 (0.0)      0.054[b](#tfn9-jir-12-127){ref-type="table-fn"}
  Hyperbaric O~2~     6 (1.8)      6 (2.8)      0 (0.0)      0.093[b](#tfn9-jir-12-127){ref-type="table-fn"}
  Ciclo sp            2 (0.6)      0 (0.0)      2 (1.7)      0.126[b](#tfn9-jir-12-127){ref-type="table-fn"}
  Tacrolimus          1 (0.3)      0 (0.0)      1 (0.9)      0.356[b](#tfn9-jir-12-127){ref-type="table-fn"}
  Stem cell therapy   1 (0.3)      1 (0.5)      0 (0.0)      1.000[b](#tfn9-jir-12-127){ref-type="table-fn"}

**Notes:**

Descriptive level of probability of chi-squared test.

Descriptive level of probability of Fisher's exact test. Data are presented as n (%).

**Abbreviations:** 5-ASA, 5-aminosalicylic acid; CD, Crohn's disease; UC, ulcerative colitis; IFX, Infliximab; MTX, methotrexate; Vedo, vedolizumab; Cico sp, Ciprofloxacin.

###### 

Extra-intestinal manifestation of inflammatory bowel disease patients

  Manifestation      n    \%     95% CI
  ------------------ ---- ------ --------------
  Dry eye            58   17.6   (13.5; 21.4)
  Kidney stones      57   17.3   (13.2; 21.4)
  Osteopenia         50   15.2   (11.3; 19.1)
  Osteoporosis       28   8.5    (5.5; 11.5)
  Erythema nodosum   18   5.5    (3.0; 7.9)
  Oral ulcers        8    2.4    (0.8; 4.1)
  Uveitis            8    2.4    (0.8; 4.1)
